[HTML][HTML] Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study
Background The BRIM-3 trial showed improved progression-free survival (PFS) and overall
survival (OS) for vemurafenib compared with dacarbazine in treatment-naive patients with …
survival (OS) for vemurafenib compared with dacarbazine in treatment-naive patients with …
[PDF][PDF] Vemurafenib in patients with BRAF V600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study
PB Chapman, C Robert, J Larkin, JB Haanen, A Ribas… - Annals of …, 2017 - cinj.org
Background: The BRIM-3 trial showed improved progression-free survival (PFS) and overall
survival (OS) for vemurafenib compared with dacarbazine in treatment-naive patients with …
survival (OS) for vemurafenib compared with dacarbazine in treatment-naive patients with …
Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study
PB Chapman, C Robert, J Larkin, JB Haanen… - Annals of …, 2017 - zora.uzh.ch
Background: The BRIM-3 trial showed improved progression-free survival (PFS) and overall
survival (OS) for vemurafenib compared with dacarbazine in treatment-naive patients with …
survival (OS) for vemurafenib compared with dacarbazine in treatment-naive patients with …
Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study.
PB Chapman, C Robert, J Larkin, JB Haanen… - Annals of oncology …, 2017 - folia.unifr.ch
Results Between 4 January 2010 and 16 December 2010, a total of 675 patients were
randomized to vemurafenib (n= 337) or dacarbazine (n= 338, of whom 84 crossed over to …
randomized to vemurafenib (n= 337) or dacarbazine (n= 338, of whom 84 crossed over to …
[引用][C] Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study
PB CHAPMAN, C ROBERT, J LARKIN… - Annals of …, 2017 - jglobal.jst.go.jp
Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final
overall survival results of the randomized BRIM-3 study | Article Information | J-GLOBAL Art J-GLOBAL …
overall survival results of the randomized BRIM-3 study | Article Information | J-GLOBAL Art J-GLOBAL …
[HTML][HTML] Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study
PB Chapman, C Robert, J Larkin… - Annals of …, 2017 - annalsofoncology.org
Background The BRIM-3 trial showed improved progression-free survival (PFS) and overall
survival (OS) for vemurafenib compared with dacarbazine in treatment-naive patients with …
survival (OS) for vemurafenib compared with dacarbazine in treatment-naive patients with …
[HTML][HTML] Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study
PB Chapman, C Robert, J Larkin, JB Haanen… - Annals of …, 2017 - ncbi.nlm.nih.gov
Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall
survival results of the randomized BRIM-3 study - PMC Back to Top Skip to main content NIH …
survival results of the randomized BRIM-3 study - PMC Back to Top Skip to main content NIH …
Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study.
PB Chapman, C Robert, J Larkin… - Annals of Oncology …, 2017 - europepmc.org
Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall
survival results of the randomized BRIM-3 study. - Abstract - Europe PMC Sign in | Create an …
survival results of the randomized BRIM-3 study. - Abstract - Europe PMC Sign in | Create an …
[引用][C] Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study
PB Chapman, C Robert, J Larkin, JB Haanen… - Annals of …, 2017 - cir.nii.ac.jp
Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall
survival results of the randomized BRIM-3 study | CiNii Research CiNii 国立情報学研究所 学術 …
survival results of the randomized BRIM-3 study | CiNii Research CiNii 国立情報学研究所 学術 …
Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study.
P Chapman, C Robert, J Larkin, J Haanen, A Ribas… - 2017 - christie.openrepository.com
Vemurafenib in patients with BRAF mutation-positive metastatic melanoma: final overall survival
results of the randomized BRIM-3 Page 1 ORIGINAL ARTICLE Vemurafenib in patients with BRAF …
results of the randomized BRIM-3 Page 1 ORIGINAL ARTICLE Vemurafenib in patients with BRAF …